OxPOS: Oxford Precision Oncology for Sarcoma
Research type
Research Study
Full title
OXFORD PRECISION ONCOLOGY FOR SARCOMA (OX-POS); PROSPECTIVE, LONGITUDINAL, OBSERVATIONAL STUDY WITH INTEGRATION OF NAVIFY® PATHWAY DECISION SUPPORT
IRAS ID
299632
Contact name
Andrew Bassim HASSAN
Contact email
Sponsor organisation
University of Oxford
Duration of Study in the UK
4 years, 0 months, 1 days
Research summary
The question addressed in this study is whether the integration of new technologies can result in
measurable improvements in care for participants with a rare cancer called sarcoma. These technologies
include new cancer DNA and RNA sequencing tests that determine the basis of an individual cancer, new
analysis of body scans and new deeper integrated analysis of all the data obtained, including cost
effectiveness. Sarcoma patients will be invited to consent by sarcoma clinicians that are involved in their
diagnosis and treatment in the Oxford sarcoma multidisciplinary team. All study participants (patients) will
receive standard of care treatment throughout. They will be asked to provide; an extra blood test and use
of excess diagnostic material for sequencing tests, consent for a study specific additional CT or ultrasound
guided biopsy only if their sarcoma later progresses, their data in the electronic patient record including
scan images and completion of study questionnaires. All the data collected will comply with data
protection legislation including being pseudonymised (direct identifiers removed), but a link to direct
identifiers remains. Depending on participant consent, study analysed data may therefore be returned for
use by the standard of care Sarcoma MDT and communication back to the study participant and GP.
Participants will be invited to complete standard questionnaires related to their psychological wellbeing
and quality of life before and after a clinic appointment that will communicate the personalised study
results. The way the results are communicated to participants will also be assessed by participant
questionnaires after the clinic in order to improve the quality of this process. How the MDT clinicians
actively make MDT decisions using the new data available will also be assessed using questionnaires and a
semi-structured interview. All of the pseudonymised data is stored securely in the hospital clinical data
warehouse and transferred for analysis using software in a secure UK based data cloud. The analysis may
offer additional findings that are helpful to the care of each participant, and to the care of sarcoma patients
overall.REC name
South Central - Oxford C Research Ethics Committee
REC reference
22/SC/0054
Date of REC Opinion
11 Mar 2022
REC opinion
Favourable Opinion